Bezafibrate sustained release - Aralez Pharmaceuticals

Drug Profile

Bezafibrate sustained release - Aralez Pharmaceuticals

Alternative Names: Bezalip SR

Latest Information Update: 21 Mar 2016

Price : $50

At a glance

  • Originator Roche
  • Developer Allergan; Roche
  • Class Antihyperlipidaemics; Benzamides; Fibric acid derivatives; Phenylbutyrates; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Hypertriglyceridaemia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 11 Nov 2013 The US FDA clears an IND application by Tribute Pharmaceuticals for Hypertriglyceridaemia
  • 11 Nov 2013 Bezafibrate sustained release - Tribute Pharmaceuticals is available for licensing in USA as of 11 Nov 2013. http://www.tributepharma.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top